(Q39547267)

13 September 2017

title

IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma (English)

1 reference

13 September 2017

1 reference

Feng Lan

1

1 reference

13 September 2017

Le Zhang

2

1 reference

13 September 2017

Junchao Wu

3

1 reference

13 September 2017

Jie Zhang

4

1 reference

13 September 2017

Sen Zhang

5

1 reference

13 September 2017

Kai Li

6

1 reference

13 September 2017

Yanyu Qi

7

1 reference

13 September 2017

Ping Lin

8

1 reference

13 September 2017

publication date

6 May 2011

1 reference

International Journal of Colorectal Disease

13 September 2017

published in

1 reference

13 September 2017

volume

26

1 reference

13 September 2017

issue

12

1 reference

13 September 2017

page(s)

1511-1518

1 reference

https://scigraph.springernature.com/pub.10.1007/s00384-011-1232-6

13 September 2017

exact match

0 references

cites work

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

A unique role for IL-23 in promoting cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

IL-23 promotes tumour incidence and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Regulatory T-cell compartmentalization and trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Forkhead-box transcription factors and their role in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Worldwide variations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Analysis of FOXP3 reveals multiple domains required for its function as a transcriptional repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Interleukin-23 drives intestinal inflammation through direct activity on T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Foxp3 expression in p53-dependent DNA damage responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Interleukin-23 drives innate and T cell-mediated intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1232-6

Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase/signal transducer and activation of transcription pathway in human CD4 T cells.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21547355

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21547355

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00384-011-1232-6

1 reference

13 September 2017

1 reference